Literature DB >> 11426527

Second primary tumors and immune phenomena after fludarabine or 2-chloro-2'-deoxyadenosine treatment.

E Van Den Neste1, A Delannoy, W Feremans, A Ferrant, L Michaux.   

Abstract

The purine nucleoside analogs fludarabine and 2-chloro-2'-deoxyadenosine display substantial activity in the treatment of various chronic lymphoproliferative disorders. Their major toxicities are primarily immunosuppression and myelosuppression. The profound influence of these drugs on the immune system has raised questions as to the emergence of secondary neoplasms or auto-immune disorders after their use. Based on a literature review and on personal observations, this article reviews the potential clinical importance of these concerns.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11426527     DOI: 10.3109/10428190109097653

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

Review 1.  Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.

Authors:  Tadeusz Robak
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

2.  Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine.

Authors:  Pavan Kumar Bhamidipati; Elias Jabbour; Sergej Konoplev; Zeev Estrov; Jorge Cortes; Naval Daver
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-12-14

3.  Auto-immune neutropenia associated with metformin in a patient with splenic marginal zone lymphoma.

Authors:  Franck Laporte; Safouane Hamdi; Françoise Oksman; Françoise Huguet
Journal:  Pharm World Sci       Date:  2008-04-05

Review 4.  Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs.

Authors:  Candida Vitale; Maria Chiara Montalbano; Chiara Salvetti; Elia Boccellato; Valentina Griggio; Mario Boccadoro; Marta Coscia
Journal:  Cancers (Basel)       Date:  2020-01-23       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.